Erectile Dysfunction Is a Vascular and Metabolic Signal, Not Just Low T

In contemporary medicine, the conversation around erectile dysfunction is frequently a short one. The patient describes the symptom. A pharmaceutical is offered. The conversation ends. For some men, this is sufficient. For most, it leaves the underlying disease untreated and a meaningful window for cardiovascular prevention closed.

The clinical literature has been clear for two decades: erectile dysfunction is, more than anything else, a vascular phenomenon. The penile arterial system is among the smallest and most flow-sensitive in the body. Endothelial dysfunction, atherosclerosis, and microvascular disease show up there before they show up anywhere else. By the time chest pain or claudication arrives, the disease is often advanced. By the time erectile function declines, the disease is often early — and reversible.

This is the central reason an erectile dysfunction evaluation deserves more than a prescription pad.

What ED Predicts

The Massachusetts Male Aging Study, the Princeton Consensus, and a substantial body of prospective evidence have established that men with erectile dysfunction have markedly elevated risk of subsequent cardiovascular events. The relative risk is on the order of 1.5 to 2 across most studies, with a stronger association in younger men. The lead time — the average interval between ED onset and a major adverse cardiovascular event — is approximately three to five years.

That lead time is the clinical opportunity. A man whose erectile function has declined and whose physician orders only a testosterone level and a PDE5 inhibitor has been managed but not evaluated. A man whose physician treats ED as a window into the cardiovascular and metabolic system has access to a clinical lead time that very few other symptoms provide.

The implication is not that every man with ED needs a cardiac catheterization. The implication is that ED should trigger a careful evaluation of cardiovascular risk factors and an honest conversation about modifiable contributors.

What a Proper Evaluation Includes

A thorough evaluation considers four overlapping mechanisms.

Vascular. Endothelial dysfunction, microvascular disease, and atherosclerosis affecting the cavernosal arteries. The relevant labs include lipid panel with ApoB, lipoprotein(a), hs-CRP, fasting insulin, HbA1c, and homocysteine. Office assessment of blood pressure, body composition, and waist circumference. In selected cases, carotid intima-media thickness, coronary calcium score, or specialized vascular studies.

Endocrine. Testosterone, free testosterone, SHBG, LH, FSH, prolactin, estradiol, thyroid panel, and morning cortisol when indicated. Hypogonadism contributes in many men, but rarely as the sole explanation. The thorough low testosterone workup is the foundation, with the recognition that ED can occur with normal testosterone, and low testosterone can occur without ED.

Metabolic. Insulin resistance is one of the most common and most modifiable contributors to ED. Visceral adiposity, hepatic steatosis, and metabolic syndrome cluster with erectile dysfunction with high frequency. The relationship between insulin resistance and testosterone is bidirectional — the metabolic correction often resolves both.

Neurological and psychogenic. Diabetic neuropathy, post-surgical nerve injury (particularly post-prostatectomy), and certain medications contribute. Psychogenic factors — performance anxiety, relationship strain, depression — coexist frequently and require honest assessment.

A history that distinguishes situational from global ED, presence or absence of nocturnal and morning erections, onset pattern (gradual versus abrupt), and medication history is informative and often diagnostic.

Where Treatment Goes Wrong

The default treatment pathway in many practices is a PDE5 inhibitor — sildenafil, tadalafil, or vardenafil. These are effective, well-studied medications. They work by enhancing the nitric oxide pathway that the body itself produces during sexual response. They are appropriately prescribed for many patients.

Where the treatment pathway goes wrong is when the medication is offered without addressing the underlying disease. A man who responds to sildenafil but whose ApoB is 130 and whose fasting insulin is 22 has a cardiovascular trajectory that the prescription does not change. The medication restores function. It does not slow the disease.

The complementary risk is the patient who is offered testosterone replacement on the basis of ED with a borderline-low testosterone, without a comprehensive evaluation of vascular and metabolic factors. Testosterone may improve libido and overall well-being. It does not reliably resolve ED when the root cause is endothelial. The patient feels better. The arteries continue to deteriorate. The eventual cardiovascular event is not prevented.

The right treatment is built around the right diagnosis.

What a Comprehensive Plan Looks Like

A comprehensive ED plan addresses each of the contributing mechanisms identified in evaluation.

Foundational metabolic and vascular intervention. Resistance training and cardiovascular fitness are non-negotiable. Body composition correction, with attention to visceral fat. Mediterranean-pattern nutrition with adequate protein. Sleep restoration — sleep apnea screening when indicated, given its frequency in this population. Smoking cessation. Alcohol moderation. Where appropriate, pharmacotherapy for lipid optimization, blood pressure control, and metabolic correction. GLP-1 therapy is increasingly relevant in the metabolically dysfunctional patient with ED.

Endocrine optimization where indicated. Testosterone optimization, when low T is contributing, is one component of the plan and not the whole plan. Thyroid optimization when subclinical hypothyroidism is contributing. Cortisol management when HPA-axis dysfunction is contributing.

Symptomatic support. PDE5 inhibitors as needed. Daily low-dose tadalafil is reasonable in many patients and has the secondary benefit of mild improvement in lower urinary tract symptoms and possible endothelial benefit with chronic use. Other interventions — shockwave therapy, intracavernosal injections, vacuum devices — have specific roles in selected patients.

Cardiovascular surveillance. Periodic reassessment of cardiovascular risk markers. Coronary calcium scoring in men over forty with risk factors and a positive family history. Stress testing when indicated. The ED diagnosis is the entry point into a longer cardiovascular conversation.

The Vis Viva framework captures this through three domains. Sensus tracks the symptom directly — function, libido, mood, relationship satisfaction. Pulsus tracks the lipid, metabolic, hormonal, and inflammatory markers that define cardiovascular trajectory. Virtus tracks the functional capacity — exercise tolerance, body composition, sexual function — that integrates the success of intervention.

What to Ask Your Physician

If you are evaluating ED in yourself or a partner, several questions move the conversation forward.

What is my cardiovascular risk profile, including ApoB, lipoprotein(a), and fasting insulin? What is my full hormonal panel — total and free testosterone, SHBG, LH, FSH, prolactin, estradiol, thyroid? What is my metabolic profile, including HOMA-IR and HbA1c? What is the plan to address modifiable risk factors, not just to manage the symptom? Have I been screened for sleep apnea?

A physician who is willing to use ED as an entry point into the broader picture is treating the disease. A physician who treats ED as an isolated complaint is treating the symptom.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Signs of Low Testosterone Most Men Ignore
• How Insulin Resistance Is Quietly Destroying Your Testosterone
• Testosterone and Cardiovascular Health

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.